NATURE REVIEWS CANCER

Scope & Guideline

Pioneering Knowledge in Cancer Prevention and Treatment

Introduction

Delve into the academic richness of NATURE REVIEWS CANCER with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1474-175x
PublisherNATURE PORTFOLIO
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2001 to 2024
AbbreviationNAT REV CANCER / Nat. Rev. Cancer
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressHEIDELBERGER PLATZ 3, BERLIN 14197, GERMANY

Aims and Scopes

NATURE REVIEWS CANCER aims to provide comprehensive, high-quality reviews on the latest advancements in cancer research, focusing on a wide array of topics that intersect with various disciplines. The journal emphasizes both fundamental and translational insights that can impact clinical practices and cancer management.
  1. Cancer Biology and Mechanisms:
    The journal explores the fundamental biological processes underlying cancer, including cellular signaling, genetic mutations, and tumor microenvironment interactions.
  2. Therapeutic Strategies and Innovations:
    It investigates novel therapeutic approaches, including targeted therapies, immunotherapies, and emerging treatment modalities, aiming to enhance patient outcomes.
  3. Epidemiology and Public Health:
    Research on cancer epidemiology, risk factors, and public health implications is a core focus, addressing disparities and the impact of environmental factors on cancer incidence.
  4. Translational Research and Clinical Applications:
    The journal emphasizes the translation of laboratory findings into clinical practice, highlighting studies that bridge the gap between research and patient care.
  5. Emerging Technologies in Cancer Research:
    NATURE REVIEWS CANCER discusses the application of cutting-edge technologies such as genomics, proteomics, and artificial intelligence in cancer research and treatment.
  6. Patient-Centric Research and Care:
    The journal promotes research that centers on patient experiences, outcomes, and the integration of patient perspectives in cancer care.
The landscape of cancer research is continually evolving, and NATURE REVIEWS CANCER reflects this dynamism through its recent publications that spotlight emerging themes and trends. These areas indicate a shift in focus towards innovative approaches and interdisciplinary research.
  1. Immunotherapy and Immune Microenvironment:
    There has been a significant increase in studies focusing on the role of the immune system in cancer, particularly regarding immunotherapy and the tumor immune microenvironment.
  2. AI and Machine Learning Applications:
    The integration of artificial intelligence and machine learning in cancer diagnosis, treatment planning, and research methodologies has gained momentum, reflecting technological advancements in the field.
  3. Patient-Derived Models and Organoids:
    Research utilizing patient-derived tumor models and organoids is on the rise, emphasizing personalized medicine and the importance of studying cancer in a more physiologically relevant context.
  4. Microbiome and Cancer Interactions:
    An emerging theme is the exploration of the gut and tumor microbiome's role in cancer initiation and progression, highlighting the importance of microbiota in cancer biology.
  5. Sex and Racial Disparities in Cancer:
    There is a growing emphasis on understanding how sex and racial disparities affect cancer outcomes, treatment responses, and genetic predispositions, aiming for more equitable healthcare solutions.

Declining or Waning

While NATURE REVIEWS CANCER covers a broad spectrum of cancer-related topics, certain areas have shown a decline in publication frequency or focus over the recent years. This may reflect shifts in research priorities, funding availability, or emerging scientific interests.
  1. Traditional Chemotherapy:
    Research focusing solely on traditional chemotherapy regimens has decreased, as newer targeted and immunotherapeutic strategies gain prominence.
  2. Basic Cancer Genetics:
    While genetics remains crucial, the emphasis has shifted from basic genetic studies to more complex interactions involving epigenetics and the tumor microenvironment.
  3. Single-Agent Therapies:
    There is a waning interest in studies that focus on single-agent therapies, as combination therapies and multi-modal approaches are becoming more favored in the literature.
  4. Non-Clinical Models:
    Research that relies solely on non-clinical models without translational implications is less frequently published, with a stronger emphasis on studies that can inform clinical practice.
  5. Conventional Imaging Techniques:
    There is a notable decline in the publication of papers centered on conventional imaging techniques, as advanced imaging technologies and multiplex approaches are increasingly favored.

Similar Journals

Nature Cancer

Fostering Innovation in Cancer Biology
Publisher: NATURE PORTFOLIOISSN: Frequency: 12 issues/year

Nature Cancer, published by NATURE PORTFOLIO, stands at the forefront of oncological research with a robust impact within the scientific community. As an esteemed journal with impressive rankings—#12 in Medicine (Oncology) and #8 in Biochemistry, Genetics and Molecular Biology (Cancer Research) according to Scopus, placing it within the 97th and 96th percentiles respectively—Nature Cancer boasts a Q1 category status in both Cancer Research and Oncology for 2023. The journal's commitment to advancing cancer research is crucial, promoting high-quality, peer-reviewed studies that address the complexities of cancer biology and treatment. By facilitating open access to impactful findings, Nature Cancer aims to foster collaboration and inspire innovative approaches among researchers, professionals, and students alike, making significant strides in the global fight against cancer. As this pivotal publication continues its converged years from 2020 to 2024, it heralds a future ripe with transformative insights and breakthroughs in the vital field of oncology.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Exploring Breakthroughs in Cancer Science and Patient Care.
Publisher: SPRINGERISSN: 0171-5216Frequency: 12 issues/year

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

Molecular & Cellular Oncology

Connecting researchers to the forefront of oncology.
Publisher: TAYLOR & FRANCIS INCISSN: Frequency: 6 issues/year

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

Cancer Biology & Medicine

Driving Innovation in Oncology Studies
Publisher: CHINA ANTI-CANCER ASSOCISSN: 2095-3941Frequency: 4 issues/year

Cancer Biology & Medicine is a distinguished Open Access journal published by the China Anti-Cancer Association, dedicated to advancing research and understanding in the fields of Cancer Research and Oncology. Since its inception in 2012, the journal has provided a vital platform for the dissemination of high-quality research, evidenced by its impressive ranking within the Q1 and Q2 categories of oncology and cancer research as of 2023. With a significant impact factor and a Scopus ranking of #64 in Medicine/Oncology and #55 in Biochemistry, Genetics, and Molecular Biology, it plays a crucial role in shaping the future of cancer biology. By offering open access to its content, the journal ensures that pivotal research findings are readily available to researchers, professionals, and students globally, thereby fostering collaboration and innovation in cancer research. Situated in Tianjin, China, this journal is poised at the frontier of oncology research, making a significant impact through its rigorous peer-reviewed articles that address critical challenges in the field.

CANCER BIOLOGY & THERAPY

Exploring the depths of cancer biology for impactful therapies.
Publisher: TAYLOR & FRANCIS INCISSN: 1538-4047Frequency: 12 issues/year

CANCER BIOLOGY & THERAPY is a premier open-access journal published by Taylor & Francis Inc, dedicated to advancing the field of cancer research and treatment. Since its inception in 2002, the journal has evolved to provide a platform for innovative research and groundbreaking findings, addressing critical aspects of cancer biology, pharmacology, and molecular medicine. With an impressive impact factor and recognition as a Q2 journal in vital categories such as Cancer Research, Oncology, and Pharmacology, it holds significant standing in Scopus rankings, reflecting its influence and commitment to disseminating high-quality research. Offering researchers, professionals, and students a wealth of knowledge, CANCER BIOLOGY & THERAPY stands at the forefront of the fight against cancer, presenting the latest developments and therapeutic strategies vital for improving patient outcomes. Accessible to all since 2022, this journal is a must-read for anyone involved in the multifaceted arena of cancer research and treatment.

Translational Cancer Research

Catalyzing progress in oncology and imaging sciences.
Publisher: AME PUBLISHING COMPANYISSN: 2218-676XFrequency: 12 issues/year

Translational Cancer Research, published by AME Publishing Company in Hong Kong, is a pivotal journal aimed at fostering the advancement of oncology-related knowledge through the dissemination of high-quality research findings. With its ISSN 2218-676X and E-ISSN 2219-6803, this journal serves as a vital resource for researchers, professionals, and students in the fields of Cancer Research, Oncology, and Radiology, Nuclear Medicine, and Imaging. Established in 2012, the journal covers the latest breakthroughs and cross-disciplinary approaches that drive innovation in cancer treatment and diagnostics. Although currently classified in the Q4 Quartile for Cancer Research and Q3 for both Oncology and Radiology, Translational Cancer Research continuously works toward improving its academic influence and impact, evidenced by its ongoing research contributions. The journal emphasizes open access, making crucial research available to a global audience. We invite scholars and industry professionals to engage with the latest findings and discussions within these critical areas of medical science.

CANCER IMMUNOLOGY IMMUNOTHERAPY

Fostering Breakthroughs in Cancer Treatment Strategies
Publisher: SPRINGERISSN: 0340-7004Frequency: 12 issues/year

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

Cancer Cell International

Transforming Knowledge into Cancer Solutions
Publisher: BMCISSN: Frequency: 1 issue/year

Cancer Cell International, published by BMC, is a transformative open-access journal established in 2001, dedicated to advancing the field of oncology and cancer research. With its ISSN number not specified and an E-ISSN of 1475-2867, the journal proudly operates from the United Kingdom, located at CAMPUS, 4 Crinan St, London N1 9XW, England. Renowned for its rigorous peer-review process, Cancer Cell International has made significant strides, securing a Q2 ranking in Cancer Research and Q1 rankings in both Genetics and Oncology as of 2023. It ranks impressively in Scopus, featuring in the top quintile of Genetics (#37/347) and Oncology (#52/404), indicating its importance within the scientific community. The journal's broad scope caters to a diverse array of topics within cancer biology, making it an invaluable resource for researchers, professionals, and students seeking to stay at the forefront of cancer science. With a commitment to disseminating high-quality research, Cancer Cell International invites scholars to explore innovative findings and contribute to the collective effort of combating cancer.

INTERNATIONAL JOURNAL OF CANCER

Shaping the future of oncology through rigorous research.
Publisher: WILEYISSN: 0020-7136Frequency: 24 issues/year

INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.

CANCER RESEARCH

Pioneering insights into cancer biology and treatment.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 0008-5472Frequency: 24 issues/year

Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.